search

XAMAMINA * BB 6CPS 25MG

  • DOMPE' FARMACEUTICI SpA
  • 002955108
Features:


Suitable for children from 2 years.


Indicated in case of seasickness, car and train sickness.


Deductible over-the-counter drug.


Antihistamine and anticholinergic action.


















info_outline View product sheet
Final Price €8.50
Quantity
check_circle Available (7 Items)
48h
  Convenient and safe payments

Even with a credit card

  Shipping in 48h-72h all over the world

FREE in Italy over € 39.90

  Fast returns

14 days to reconsider

  Pharmaceutical experience

Always at your service

Other products Others products at unbeatable price

DOMPE' FARMACEUTICI SpA

Discover all products

XAMAMINA * BB 6CPS 25MG

Therapeutic indications

Sea, plane, car and train sickness.

Dosage and method of use

XAMAMINE 50 mg soft capsulesIn adults 1 soft capsule half an hour before travel; if necessary repeat the dose after 3-4 hours, up to a maximum of 4 soft capsules in 24 hours.XAMAMINE Children 25 mg soft capsulesIn children aged 2-6 years 1 soft capsule of Xamamina Children half an hour before travel up to a maximum of 3 times in 24 hours. In children aged 7-12 years 1-2 soft capsules of Xamamina Children half an hour before travel, up to a maximum of 2-3 times in 24 hours. Do not exceed the recommended dose.

Contraindications

Hypersensitivity to the active substance, to other antihistamines or to any of the excipients. Contraindicated in children under 2 years of age. Contraindicated during pregnancy and lactation.

Side effects

The following side effects have been reported following treatment with Xamamina:

System organ class More frequent side effects Frequent side effects Less frequent side effects
Disorders of metabolism and nutrition   Anorexia  
Psychiatric disorders     Insomnia (especially in children), Euphoria
Disorders of the nervous system Sedation, Somnolence Headache Vertigo, Tremors, Convulsions (especially in children)
Disorders of sight   Disorders of accommodation  
Cardiac disorders     Tachycardia
Vascular disorders     Hypotension
Gastrointestinal disorders   Dry mouth, Nausea  
Disorders of the skin and subcutaneous tissue   Photosensitivity, Skin reaction on allergic basis  
Renal and urinary disorders   Disorders of urination  
General Disorders and Administration Site Conditions     Asthenia

Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk ratio of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

Special warnings

The product should be administered with caution in subjects suffering from narrow-angle glaucoma, prostatic hypertrophy, urinary retention, slowing of intestinal transit, bronchial asthma, epilepsy, porphyria. The product may mask the symptoms of ototoxicity and therefore should be administered with caution in patients receiving ototoxic drugs. Soft capsules containsorbitol: Patients with rare hereditary problems of fructose intolerance should not take this medicine. Soft capsules containparabenswhich can cause allergic reactions (including delayed).

Pregnancy and breastfeeding

Pregnancy. In reproductive studies in rats and rabbits, doses 20-25 times higher than those normally used in therapy in humans did not show teratogenic effects or impaired fertility. However, no data are available on the use of the product in pregnant women. Therefore, although the teratogenicity of the product appears unlikely, the use of dimenhydrinate in pregnancy is contraindicated.Feeding time. Small amounts of dimenhydrinate pass into breast milk. Given the possible adverse events of the product in infants, the use of dimenhydrinate during lactation is contraindicated.

Expiration and retention

Store at a temperature not exceeding 25 ° C

Interactions with other drugs

The product may enhance the effects of other CNS depressants, such as alcohol, barbiturates, other hypnotics, sedatives or tranquilizers. In case of concomitant intake of these substances, attention must be paid in order to avoid additive phenomena of sedation. The product may potentiate the effects of other anticholinergic drugs, including antidepressants. If administered concomitantly with aminoglycoside antibiotics or other ototoxic drugs, dimenhydrinate can mask the first symptoms of ototoxicity, which can only be detected when the damage is irreversible (see also section 4.4).

Overdose

In case of overdose consult your doctor immediately. Sleepiness is the most usual symptom of overdosing. Toxic doses can produce: convulsion, coma and respiratory depression. If necessary, implement symptomatic therapy. When needed, respiratory assistance.

Active principles

XAMAMINE 50 mg soft capsulesOne soft capsule contains: active ingredient: dimenhydrinate 50 mg Excipients: sorbitol, parabensXAMAMINE Children 25 mg soft capsulesOne soft capsule contains: active substance: dimenhydrinate 25 mg Excipients: sorbitol, parabens For a full list of excipients, see section 6.1

Excipients

XAMAMINE 50 mg soft capsules and XAMAMINE Children 25 mg soft capsulesmacrogol 400. Shell: gelatin;partially dehydrated liquid sorbitol; ethyl sodium-parahydroxybenzoate (E215); propyl sodium parahydroxybenzoate (E 217).

002955108
7 Items

Data sheet

Packaging
children 25 mg 6 soft capsules
Product Type
HUMAN DRUG
ATC code
R06AA11
ATC description
Dimenhydrinate (ATC R06AA02 cleaves: products containing dimenhydrinate / diphenhydramine theoclate go into the new ATC. Products containing diphenhydramine chloride remain in R06AA02.
Therapeutic Group
Antiemetics
Active principle
dimenhydrinate (DC.IT) (FU)
Class
C.
Pharmaceutical form
soft capsule
Type of Administration
oral
Container
blister
Quantity
6 soft capsule
Quantity of the Active Ingredient
25MG
Recipe required
OTC - self-medication medicine